24/7 Market News Snapshot 04 November, 2024 – Nuwellis, Inc. Common Stock (NASDAQ:NUWE)

November 4, 2024

DENVER, Colo., 04 November, 2024 (247marketnews.com) – (NASDAQ:NUWE) are discussed in this article.
Nuwellis, Inc. has captured significant attention within the financial and healthcare sectors following an impressive surge in its stock price amid transformative news affecting its therapy options. On the heels of a soaring opening price of $2.23 that climbed to a striking $3.029—an increase of 122.72% from its previous close of $1.36—Nuwellis appears to be gaining strong investor confidence. This remarkable uptick, with a trading volume reaching 77.83 million shares, highlights a responsive market that is enthusiastic about the company’s innovative healthcare solutions.

Simultaneously, Nuwellis is set to benefit from a landmark announcement by the Centers for Medicare and Medicaid Services (CMS), which will significantly enhance reimbursement rates for its Aquadex SmartFlow therapy beginning January 1, 2025. The daily reimbursement rate for this essential treatment will increase dramatically by 397%, from $413 to $1,639. This adjustment marks a crucial shift, ensuring that reimbursement aligns with the actual costs of providing ultrafiltration therapy, particularly for patients experiencing fluid overload conditions.

Nestor Jaramillo, President and CEO of Nuwellis, expressed optimism regarding this adjustment, emphasizing its confirmation of the clinical effectiveness and cost efficiency of the company’s technology. He emphasized the importance of the reclassification of the therapeutic ultrafiltration CPT code 0692T, which now provides a clear reimbursement pathway for outpatient ultrafiltration therapy. This change not only expands access to a life-saving treatment for patients with chronic conditions like heart failure but also demonstrates Nuwellis’s commitment to advancing fluid management care.

Through such groundbreaking enhancements in treatment accessibility and financial viability, Nuwellis, Inc. is poised to lead innovation in patient care and improve health outcomes for individuals challenged by fluid overload nationwide.

Related news for (NUWE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.